Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 6/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585005 | 1.00 | NR1H3 (0.33) | NR1H3NR1H2HSD17B10USP2SMN1; SMN2 | |
| SCHEMBL2842337 | 0.89 | NR1H2 (0.30) | NR1H3NR1H2 | |
| SCHEMBL2838592 | 0.89 | NR1H2 (0.30) | NR1H3NR1H2 | |
| SCHEMBL585207 | 0.88 | NR1H3 (0.33) | NR1H3NR1H2HSD17B10 | |
| SCHEMBL585010 | 0.88 | NR1H3 (0.33) | NR1H3NR1H2HSD17B10 | |
| SCHEMBL1861184 | 0.80 | NR1H2 (0.34) | NR1H3NR1H2HSD17B10USP2SMN1; SMN2 | |
| SCHEMBL28449177 | 0.78 | PARP1 (0.39) | NR1H3NR1H2HSD17B10USP2SMN1; SMN2 | |
| SCHEMBL21045726 | 0.78 | PARP1 (0.39) | NR1H3NR1H2HSD17B10USP2SMN1; SMN2 | |
| SCHEMBL21045830 | 0.78 | PARP1 (0.39) | NR1H3NR1H2HSD17B10USP2SMN1; SMN2 | |
| SCHEMBL26105636 | 0.78 | PARP1 (0.39) | NR1H3NR1H2HSD17B10USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2102217-A2 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008062379-A2 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | NR1H3 419/4885NR1H2 299/4885HSD17B10 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.